Horizon Pharma and Chiesi Farmaceutici in European marketing rights agreement

Horizon Pharma has reached an agreement to sell a European subsidiary that owns the marketing rights to Procysbi (cysteamine bitartrate) delayed-release capsules and Quinsair (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.p.A. (Chiesi) for an upfront payment of $70 million, with additional potential milestone payments based on sales targets.

Read more

Horizon Pharma issues notice of allowance from USPTO for its anti-inflammatory drug

Horizon Pharma, a biopharmaceutical company focused identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, has issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 15/180,173…

Read more

Horizon’s lung infections antibiotic Quinsair available in Canada for adults with Cystic Fibrosis

Horizon Pharma and its Canadian affiliate Horizon Therapeutics Canada Limited have brought its inhalation solution for chrnic lung infection Quinsair to Canada.

Quinsair is used for chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).

Read more